KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) EBITDA (2016 - 2025)

Globus Medical's EBITDA history spans 15 years, with the latest figure at $145.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 445.02% year-over-year to $145.0 million; the TTM value through Dec 2025 reached $560.1 million, up 426.81%, while the annual FY2025 figure was $560.1 million, 426.81% up from the prior year.
  • EBITDA reached $145.0 million in Q4 2025 per GMED's latest filing, up from $119.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $215.3 million in Q2 2025 to a low of -$8.0 million in Q1 2024.
  • Average EBITDA over 5 years is $55.7 million, with a median of $43.8 million recorded in 2021.
  • The largest YoY upside for EBITDA was 4168.17% in 2024 against a maximum downside of 114.67% in 2024.
  • A 5-year view of EBITDA shows it stood at $11.4 million in 2021, then skyrocketed by 406.38% to $57.7 million in 2022, then plummeted by 59.11% to $23.6 million in 2023, then increased by 12.85% to $26.6 million in 2024, then skyrocketed by 445.02% to $145.0 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's EBITDA are $145.0 million (Q4 2025), $119.7 million (Q3 2025), and $215.3 million (Q2 2025).